almagate has been researched along with Disease Models, Animal in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (64.29) | 29.6817 |
| 2010's | 4 (28.57) | 24.3611 |
| 2020's | 1 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| Andrade, N; Araújo E Silva, PM; Crispim Ribeiro, J; de Moraes, MO; Fechine, FV; Savio, D | 1 |
| Bock, F; Bucher, F; Cursiefen, C; Hos, D; Lipp, M; Onderka, J; Parthasarathy, A | 1 |
| Criswell, MH; Hu, WZ; Li, R; Margaron, P; Steffens, TJ | 1 |
| Adelman, RA; Lu, F | 1 |
| Aguilar, E; Banin, E; Bird, A; Dorrell, MI; Friedlander, M; Gariano, R; Gasmi, M; Heckenlively, J; Jacobson, R; Ramirez, GA; Siuzdak, G; Yanes, O | 1 |
| Abdallah, W; Fawzi, AA | 1 |
| Do, DV; Khurana, RN; Nguyen, QD | 1 |
| Claes, A; Hovinga, KE; Leenders, WP; Musters, GD; Peter Vandertop, W; Richel, DJ; Stalpers, LJ; van Furth, WR; Verhoeff, JJ | 1 |
| Agostini, HT; Bates, DO; Beazley Long, N; Bevan, HS; Churchill, AJ; Floege, J; Gammons, M; Harper, SJ; Hua, J; Lehrling, C; Magnussen, AL; Rennel, ES | 1 |
| Caglar, Y; Degirmenci, E; Ozdemir, O; Sener, E; Yildiz, DK; Yilmaz, B; Yuksel, N | 1 |
| Andréasson, S; Bruun, A; Ghosh, F; Lövestam Adrian, M; Myers, AC; Ponjavic, V | 1 |
| Kaiser, PK | 1 |
| Olsen, TW | 1 |
| Adamis, AP; Bradley, J; Calias, P; Cook, G; Dowie, T; Ganley, M; Ju, M; Lange, N; Mailhos, C; Robinson, GS; Shima, DT | 1 |
2 review(s) available for almagate and Disease Models, Animal
| Article | Year |
|---|---|
Anti-VEGF therapy in proliferative diabetic retinopathy.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Diabetic Retinopathy; Disease Models, Animal; Humans; Injections; Ranibizumab; Treatment Outcome; Vascular Endothelial Growth Factor A; Vitreoretinopathy, Proliferative; Vitreous Body | 2009 |
Verteporfin photodynamic therapy and anti-angiogenic drugs: potential for combination therapy in exudative age-related macular degeneration.
Topics: Age Factors; Aged; Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Choroidal Neovascularization; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Haplorhini; Humans; Macular Degeneration; Male; Middle Aged; Photochemotherapy; Porphyrins; Prognosis; Ranibizumab; Risk Assessment; Treatment Outcome; Verteporfin; Visual Acuity | 2007 |
12 other study(ies) available for almagate and Disease Models, Animal
| Article | Year |
|---|---|
Effect of Topical Instillation of Pegaptanib Sodium Upon Inflammatory Corneal Neovascularization in Rabbits.
Topics: Administration, Topical; Angiogenesis Inhibitors; Animals; Anti-Inflammatory Agents; Aptamers, Nucleotide; Caustics; Cornea; Corneal Injuries; Corneal Neovascularization; Disease Models, Animal; Inflammation; Instillation, Drug; Male; Neovascularization, Pathologic; Prednisolone; Rabbits; Sodium Hydroxide; Treatment Outcome; Vascular Endothelial Growth Factor A | 2021 |
Blockade of the VEGF isoforms in inflammatory corneal hemangiogenesis and lymphangiogenesis.
Topics: Administration, Topical; Animals; Aptamers, Nucleotide; Cell Proliferation; Corneal Neovascularization; Disease Models, Animal; Endothelial Cells; Female; Fluorescent Antibody Technique, Indirect; Glycoproteins; Lymphangiogenesis; Membrane Transport Proteins; Mice; Mice, Inbred BALB C; Ophthalmic Solutions; Platelet Endothelial Cell Adhesion Molecule-1; Protein Isoforms; Vascular Endothelial Growth Factor A | 2014 |
Comparing pegaptanib and triamcinolone efficacy in the rat choroidal neovascularization model.
Topics: Angiogenesis Inhibitors; Animals; Aptamers, Nucleotide; Choroidal Neovascularization; Disease Models, Animal; Fluorescein Angiography; Glucocorticoids; Injections; Laser Coagulation; Male; Rats; Rats, Inbred BN; Treatment Outcome; Triamcinolone Acetonide; Vascular Endothelial Growth Factor A; Vitreous Body | 2008 |
Are intravitreal bevacizumab and ranibizumab effective in a rat model of choroidal neovascularization?
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Choroidal Neovascularization; Disease Models, Animal; Dose-Response Relationship, Drug; Fluorescein Angiography; Injections; Light Coagulation; Macular Degeneration; Ranibizumab; Rats; Rats, Inbred BN; Vascular Endothelial Growth Factor A; Vitreous Body | 2009 |
Antioxidant or neurotrophic factor treatment preserves function in a mouse model of neovascularization-associated oxidative stress.
Topics: Angiogenesis Inhibitors; Animals; Antioxidants; Aptamers, Nucleotide; Disease Models, Animal; Electroretinography; Gene Expression; Gene Expression Profiling; Gene Transfer Techniques; Lipid Peroxidation; Mice; Mice, Inbred C57BL; Mice, Knockout; Nerve Growth Factors; Opsins; Oxidative Stress; Receptors, LDL; Retina; Retinal Cone Photoreceptor Cells; Retinal Neovascularization; Retinal Pigment Epithelium; Retinal Rod Photoreceptor Cells; Retinitis Pigmentosa; Rhodopsin; Vascular Endothelial Growth Factor A | 2009 |
Anti-VEGF therapeutic approaches for diabetic macular edema.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Diabetic Retinopathy; Disease Models, Animal; Humans; Injections; Macular Edema; Ranibizumab; Treatment Outcome; Vascular Endothelial Growth Factor A; Vitreous Body | 2009 |
Tumour control by whole brain irradiation of anti-VEGF-treated mice bearing intracerebral glioma.
Topics: Angiogenesis Inhibitors; Animals; Aptamers, Nucleotide; Brain Neoplasms; Combined Modality Therapy; Disease Models, Animal; Disease-Free Survival; Female; Glioblastoma; Humans; Mice; Mice, Nude; Neoplasm Invasiveness; Neoplasm Transplantation; Neovascularization, Pathologic; Treatment Outcome; Vascular Endothelial Growth Factor A | 2009 |
VEGF-A165b is cytoprotective and antiangiogenic in the retina.
Topics: Angiogenesis Inhibitors; Animals; Animals, Newborn; Aptamers, Nucleotide; Cell Movement; Cell Survival; Cells, Cultured; Cytoprotection; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Endothelium, Vascular; Epithelial Cells; Half-Life; Humans; Insulin-Like Growth Factor Binding Protein 3; Insulin-Like Growth Factor Binding Proteins; Mice; Mice, Inbred C57BL; Rats; Recombinant Proteins; Retinal Neovascularization; Retinal Vessels; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2010 |
The impact of subconjuctivally injected EGF and VEGF inhibitors on experimental corneal neovascularization in rat model.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Conjunctiva; Corneal Neovascularization; Disease Models, Animal; Epidermal Growth Factor; Follow-Up Studies; Injections; Male; Ranibizumab; Rats; Rats, Wistar; Receptor, ErbB-2; Trastuzumab; Treatment Outcome; Vascular Endothelial Growth Factor A | 2011 |
Retinal function and morphology in rabbit after intravitreal injection of VEGF inhibitors.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Disease Models, Animal; Electroretinography; Immunohistochemistry; Intravitreal Injections; Macular Degeneration; Rabbits; Ranibizumab; Retina; Vascular Endothelial Growth Factor A | 2012 |
Treatment of exudative age-related macular degeneration: many factors to consider.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Cost of Illness; Disease Models, Animal; Drug Costs; Humans; Injections; Macular Degeneration; Ranibizumab; Vascular Endothelial Growth Factor A; Vitreous Body | 2007 |
Simultaneous but not prior inhibition of VEGF165 enhances the efficacy of photodynamic therapy in multiple models of ocular neovascularization.
Topics: Animals; Aptamers, Nucleotide; Choroidal Neovascularization; Chromatography, High Pressure Liquid; Cornea; Corneal Neovascularization; Disease Models, Animal; Drug Therapy, Combination; Male; Mice; Mice, Inbred C57BL; Photochemotherapy; Photosensitizing Agents; Porphyrins; RNA, Messenger; Thromboplastin; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1; Verteporfin | 2008 |